Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Yong Ho Lee has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to a distinct examiner and a distinct art unit. The busiest examiner, CHEN, CATHERYNE, is responsible for the 1 pending office action. This singular focus indicates that the applicant's current prosecution is limited to a specific examiner and art unit.
For practitioners, this means there is no internal data from other pending matters to compare examiner behavior or art unit standards. The prosecution strategy is entirely dependent on the interaction with CHEN, CATHERYNE. This concentration suggests a targeted approach to patenting within the Biotechnology & Pharmaceuticals sector. Without additional pending matters, the applicant lacks a broader footprint across different USPTO divisions. The outcome of this single case will define the current success of the portfolio in this technology area.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHEN, CATHERYNE | 1 | 37.5% | +17.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18839691 | COMPOSITION COMPRISING COFFEE EXTRACT FOR SUPPRESSING POSTPRANDIAL BLOOD SUGAR RISE | CHEN, CATHERYNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18839691 | COMPOSITION COMPRISING COFFEE EXTRACT FOR SUPPRESSING POSTPRANDIAL BLOOD SUGAR RISE | CHEN, CATHERYNE | — |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18839691 | COMPOSITION COMPRISING COFFEE EXTRACT FOR SUPPRESSING POSTPRANDIAL BLOOD SUGAR RISE | CHEN, CATHERYNE | 1655 | §101§102§103§112 | Non-Final OA | — | Pending | Sep 26, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialYong Ho Lee has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Catheryne Chen has the most, with 1 of Yong Ho Lee's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
